利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

34 条记录 (耗时 0.059 秒)

    METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION
    1.
    发明公开
    METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION 审中-公开

    公开(公告)号：US20240076408A1

    公开(公告)日：2024-03-07

    申请号：US18312891

    申请日：2023-05-05

    申请人： Omeros Corporation ,  University of Leicester

    发明人： Hans-Wilhelm Schwaeble ,  Clark E. Tedford ,  James B. Parent

    IPC分类号： C07K16/40 ,  A61K39/395

    CPC分类号： C07K16/40 ,  A61K39/3955 ,  A61K2039/505

    摘要： In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.

    Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
    3.
    发明申请
    Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation 审中-公开

    公开(公告)号：US20180291111A1

    公开(公告)日：2018-10-11

    申请号：US15909423

    申请日：2018-03-01

    申请人： Omeros Corporation ,  University of Leicester

    发明人： Gregory A. Demopulos ,  Hans-Wilhelm Schwaeble ,  Clark E. Tedford ,  James Brian Parent

    IPC分类号： C07K16/40

    摘要： In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.

    Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
    5.
    发明申请
    Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation 审中-公开
    用于治疗与MASP-2依赖性补体激活相关的病症的方法

    公开(公告)号：US20140056873A1

    公开(公告)日：2014-02-27

    申请号：US13790756

    申请日：2013-03-08

    申请人： OMEROS CORPORATION ,  UNIVERSITY OF LEICESTER

    发明人： Hans-Wilhelm Schwaeble ,  Clark E. Tedford ,  James Brian Parent

    IPC分类号： A61K39/395

    CPC分类号： C07K16/40 ,  A61K39/3955 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2317/92

    摘要： In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.

    摘要翻译： 一方面，本发明提供抑制活体受试者中MASP-2依赖性补体活化的作用的方法。 所述方法包括向有需要的受试者施用一定量的有效抑制MASP-2依赖性补体活化的MASP-2抑制剂的步骤。 在一些实施方案中，MASP-2抑制剂抑制与MASP-2介导的替代补体途径活化相关的细胞损伤，同时保持免疫系统的经典（C1q依赖）途径组分完整。 在另一方面，本发明提供了用于抑制凝集素依赖性补体活化的作用的组合物，其包含治疗有效量的MASP-2抑制剂和药学上可接受的载体。